MRT68921: A Dual ULK1/2 Kinase Inhibitor for Precise Autophagy Research

Executive Summary: MRT68921 is a dual inhibitor of ULK1 and ULK2 kinases with IC₅₀ values of 2.9 nM and 1.1 nM, respectively, and is optimized for preclinical autophagy research (APExBIO, product page). It selectively blocks autophagy initiation by suppressing ATG13 phosphorylation and LC3 flux in wild-type cells but not in ULK1 mutant cells (M92T) (Park et al., 2023). MRT68921 is insoluble in water and ethanol but soluble in DMSO at ≥2.18 mg/mL with gentle warming and ultrasonic treatment. It demonstrates high selectivity for ULK1/2 over other kinases in the context of autophagy modulation, despite inhibiting TBK1/IKK and some AMPK-related kinases by >80%. No in vivo or clinical data are available; MRT68921 is for research use only. APExBIO supplies MRT68921 (SKU B6174) as a hydrochloride salt for laboratory use.

Biological Rationale

Autophagy is a conserved cellular degradation process critical for maintaining homeostasis, especially under stress conditions such as nutrient deprivation. The process removes damaged organelles and long-lived proteins, contributing to cell survival and adaptation (Park et al., 2023). The initiation of autophagy is orchestrated by the serine/threonine protein kinases ULK1 and ULK2, which form the core of the autophagy initiation complex. Under energy stress, autophagy induction is tightly regulated by the interplay between mTORC1 (a negative regulator) and AMPK (an energy sensor). Contrary to longstanding models, recent evidence indicates that AMPK activation suppresses, rather than activates, ULK1-mediated autophagy induction in energy-depleted cells (Park et al., 2023). This underscores the importance of precise, selective inhibition of ULK1/2 to dissect autophagy regulation and its role in cellular energy management.

Mechanism of Action of MRT68921

MRT68921 functions as a dual ULK1/2 kinase inhibitor, binding to the ATP-binding sites of both ULK1 and ULK2 with nanomolar affinity (IC₅₀ ULK1: 2.9 nM; ULK2: 1.1 nM; conditions: in vitro kinase assays, 25°C, pH 7.5) (APExBIO). In cellular systems, MRT68921 suppresses phosphorylation of ATG13, a direct ULK1 substrate, and blocks LC3 flux, an established readout for autophagic activity. These effects are observed in wild-type cells, but not in cells expressing the ULK1 M92T mutant, confirming target specificity (internal review). While MRT68921 also inhibits TBK1/IKK and certain AMPK-related kinases, studies in LKB1-knockout mouse embryonic fibroblasts (MEFs) demonstrate that autophagy blockade is primarily mediated through ULK1/2 inhibition, not off-target kinase effects (Park et al., 2023).

Evidence & Benchmarks

• MRT68921 inhibits ULK1 kinase activity in vitro with an IC₅₀ of 2.9 nM (APExBIO, product data).
• MRT68921 inhibits ULK2 kinase activity in vitro with an IC₅₀ of 1.1 nM (APExBIO, product data).
• MRT68921 blocks autophagy initiation, as measured by ATG13 phosphorylation inhibition and LC3 flux suppression in wild-type cells (Park et al., 2023).
• In LKB1-knockout MEFs, MRT68921 retains autophagy inhibition, indicating primary specificity for ULK1/2 over AMPK-related kinases (Park et al., 2023).
• MRT68921 is insoluble in water and ethanol but dissolves at ≥2.18 mg/mL in DMSO with gentle warming and sonication (APExBIO, solubility data).
• No in vivo or clinical efficacy or safety data for MRT68921 are available as of June 2024 (APExBIO, product page).
• AMPK activation inhibits ULK1 activity, opposing previous models, refining the rationale for using selective ULK1/2 inhibitors like MRT68921 (Park et al., 2023).

This article expands upon previous internal reviews (MRT68921: Dual ULK1/2 Inhibitor) by integrating new evidence on AMPK-ULK1 regulation, clarifying scenarios where MRT68921 provides unique mechanistic insights.

Applications, Limits & Misconceptions

MRT68921 is intended for preclinical laboratory use in the study of autophagy, particularly for dissecting the initiation phase regulated by ULK1 and ULK2. Applications include mechanistic studies, drug screening, and validation of autophagy pathway components using ATG13 phosphorylation and LC3 flux as endpoints. The compound is suitable for use in mammalian cell lines, including wild-type and genetically modified systems. However, MRT68921's lack of water and ethanol solubility necessitates DMSO-based formulations (scenario guide). No in vivo, animal, or clinical trial data exist; thus, it is not recommended for translational or therapeutic use.

Common Pitfalls or Misconceptions

• MRT68921 does not induce autophagy; it blocks initiation by inhibiting ULK1/2.
• AMPK activation does not mimic MRT68921 inhibition; AMPK suppresses ULK1, but via a different regulatory axis.
• MRT68921's observed effects in non-mammalian models or whole organisms have not been validated.
• Solubility in water or ethanol is negligible; DMSO is required for experimental use.
• Autophagy-independent effects via TBK1/IKK or AMPK-related kinases are possible at high concentrations, but not primary under assay-standard conditions.

Workflow Integration & Parameters

MRT68921 (SKU B6174) is supplied as a hydrochloride salt (molecular weight: 434.58; formula: C₂₅H₃₄N₆O·xHCl) and should be stored at -20°C. Prepare working stocks in DMSO at ≥2.18 mg/mL. Use gentle warming (37°C) and ultrasonic treatment to ensure dissolution. For cell-based assays, dilute DMSO stocks into culture medium to achieve final concentrations in the 1–100 nM range; maintain DMSO at ≤0.1% (v/v) to avoid cytotoxicity. Monitor autophagy inhibition via reduction in ATG13 phosphorylation and LC3-II formation using immunoblotting or fluorescence microscopy (advanced strategies), noting that the optimal readout depends on cell type and genetic background. APExBIO recommends MRT68921 strictly for preclinical research applications. For scenario-driven troubleshooting and assay optimization, see detailed guides (Advancing Preclinical Autophagy Inhibition).

Conclusion & Outlook

MRT68921 is a validated, high-affinity dual ULK1/2 inhibitor that enables precise dissection of autophagy initiation in mammalian cells. Its high potency, selectivity, and compatibility with standard cell-based autophagy assays make it an essential tool for preclinical research. As new insights into the AMPK-ULK1 axis reframe autophagy regulation, compounds like MRT68921 will remain vital for clarifying pathway dynamics. No evidence supports use beyond laboratory research; future studies may expand its applications as pathway knowledge advances.